Please login to the form below

Not currently logged in


This page shows the latest ixazomib news and features for those working in and with pharma, biotech and healthcare.

Takeda can't sway NICE on oral myeloma therapy Ninlaro

Takeda can't sway NICE on oral myeloma therapy Ninlaro

The agency reiterated its position that Ninlaro (ixazomib) is not cost-effective as a treatment for relapsed or refractory multiple myeloma, and that Takeda had not been able to persuade it

Latest news

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....